Safety and Efficacy of Xalkori ROS1

Summary

The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.

Eligibility

Inclusion Criteria:

* patients with unresectable progressive/recurrent NSCLC who are naive to XALKORI and whose tumor is ROS1 gene positive

Exclusion Criteria:

* Patients with past history of hypersensitivity to any of the ingredients of XALKORI

Conditions3

Interventions1

Related trials

• A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients — Nuvation Bio Inc.
• ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma — Hunan Province Tumor Hospital
• Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) — Canadian Cancer Trials Group
• Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC — Hunan Province Tumor Hospital
• Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. — Sun Yat-sen University
• Study of Crizotinib for ROS1 and MET Activated Lung Cancer — University Health Network, Toronto
• Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer — Oslo University Hospital
• The Drug Rediscovery Protocol (DRUP Trial) — The Netherlands Cancer Institute

Browse More Trials